Reportlinker Adds The Hepatitis Market Outlook to 2015: Competitive Landscape, Market Size, Pipeline Analysis and Growth Opportunities
NEW YORK, Nov. 22, 2010 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:
The Hepatitis Market Outlook to 2015 provides comprehensive coverage of the hepatitis market, incorporating disease overview and detailed epidemiological analyses of the various hepatitis types. This report makes a wide-ranging assessment of the marketed product portfolio, R&D pipeline, market share data, sales forecast and competitive landscape for the major players. Furthermore, it highlights the key market and R&D trends that may influence treatment sales; with a thorough analysis of the competitive dynamics of leading brands, in order to enable the reader to identify growing brands, key drug classes and leading players through 2015. The Hepatitis market may be classified as viral and non- viral hepatitis, on the basis of causative agents. Out of the six different kinds of viral hepatitis, A, B, C, D, E, and G, hepatitis A, B and C remains the most common infections prevalent across the globe.
Despite, a significant number of Hepatitis cases going unreported due to the asymptomatic nature of the disease about 1.4m cases of acute hepatitis A are reported every year while the number of chronic hepatitis B cases is 350m and hepatitis C is 170m. Hepatitis C has become one of the major focus areas for pharmaceutical companies because of high number of unmet needs for improved treatments. Although, most of the hepatitis infected population is in underdeveloped or developing countries, the market share of these countries in the global hepatitis market is relatively lower, due to the limited access to healthcare facilities resulting in significant un-diagnosed population. In terms of product pipeline, the hepatitis market has witnessed a lot of activity, with promising new drugs under late stages of development. The potential for market success is largely attributable to a large patient population, which requires long term treatment, and significant unmet need. Hepatitis C is the major indication in the hepatitis market with promising products in development. Presently, pegylated interferon commonly used in combination with the ribavirin is the standard of care for hepatitis C treatment.
This report provides in depth coverage of the hepatitis market, incorporating a disease overview and detailed epidemiological analyses of the various hepatitis types. It makes a thorough assessment of the marketed product portfolio, R&D pipeline, market share data, sales forecast and competitive landscape for the major players. It highlights the key market trends that will drive sales. rbhc0285
Scope of this research
* Develop insight into hepatitis patient potential with coverage of epidemiology of all major hepatitis types in the seven major pharmaceutical markets.
* Discover how recent events are affecting the performance of major products, and how their marketers are confronting competitive changes in the market.
* Compare the franchises of top pharmaceutical marketers, and evaluate how the market shares of the leading companies will change over the next 5 years.
* Gain up-to-date competitive intelligence on the hepatitis market and understand the major issues affecting its growth.
* Analyze the pipeline and marketed products of leading players and discover which will perform best through to 2015 with this report's sales forecasts.
Research and analysis highlights
The global hepatitis market in 2009 was valued at around $5bn, and is forecast to grow at a CAGR of more than 10% between 2009–15. These sales are being driven by products in the viral hepatitis class.
Sales in the hepatitis market are largely concentrated in the top 10 brands. These brands accounted for more than 80% of total sales. The leading product by sales in this market was Roche's Pegasys followed by Merck's Pegintron.
New pipeline compounds are expected to shorten treatment duration and improve the side effect and tolerability profile of treatment. The two most promising developmental products are telaprevir (J&J, Vertex) and boceprevir (Merck & Co) both indicated for hepatitis C.
Key reasons to purchase this research
* How is the prevalent population for hepatitis expected to change in the next five years?
* Which companies led the market for hepatitis therapies in 2009 and how are they forecast to perform through to 2015?
* What are the most promising products in development for the treatment of hepatitis and what are their forecast sales?
* How big is the generics market for hepatitis in the 7MM and which companies lead this market?
* Which vaccines lead the market for hepatitis vaccination and which companies market these products?
Table of Contents
About the author 2
Disclaimer 2
Executive summary 11
Overview and epidemiology of hepatitis 11
Global market analysis 12
Pipeline analysis 13
Competitive landscape 14
Scope and methodology 15
Scope 15
Methodology 15
Chapter 1 Overview and epidemiology of hepatitis 16
Summary 16
Introduction 17
Hepatitis A 17
Overview 17
Diagnosis and treatment 18
Epidemiology 19
Hepatitis B 20
Overview 20
Diagnosis and treatment 21
Epidemiology 22
Forecast epidemiology 23
Hepatitis C 25
Overview 25
Diagnosis and treatment 26
Epidemiology 27
Forecast epidemiology 28
Hepatitis D 30
Overview 30
Diagnosis and treatment 30
Hepatitis E 30
Overview 30
Diagnosis and treatment 31
Chapter 2 Global market analysis 32
Summary 32
Introduction 33
Market analysis by country 33
Market analysis by drug class 36
Leading brand dynamics 39
Pegasys (peginterferon alfa-2a) – Roche 40
Pegintron (peginterferon alfa-2b) – Merck 41
Baraclude (entecavir), – BMS 42
Hepsera (adefovir dipivoxil) – Gilead 43
Rebetol (ribavirin) – Merck 44
Viread (tenofovir disoproxil fumarate) – Gilead Sciences 44
Copegus (ribavirin) – Roche 45
Engerix B – GSK 45
Twinrix – GSK 46
Leading brands by drug class 47
Key recent events in the hepatitis market 49
Launch of Vertex's telaprevir expected to positively impact hepatitis market dynamics 49
BMS acquires ZymoGenetics for $885m 49
The FDA grants fast track designation to Pharmasset's PSI-7977 for the treatment of chronic HCV 49
Development program for therapeutic intranasal vaccine for the treatment of hepatitis B 50
Novartis discontinues the development of Joulferon/Zalbin on safety and efficacy concerns 50
GSK signs microRNA deal with Regulus for HCV 50
Government initiatives to curb the incidence of hepatitis 51
Generic hepatitis market in 7MM 51
Global hepatitis market sales forecast 54
Leading hepatitis drugs sales forecast 55
Chapter 3 Pipeline analysis 56
Summary 56
Introduction 57
Key trends in the R&D 57
Treatment-failure population to present significant opportunity 57
End stage renal disease (ESRD) patients expected to present high potential 58
Despite introduction of novel treatments, PEG/RBV will remain the standard of care 58
Promising developments in the hepatitis C pipeline 58
Product differentiation will hold the key to success in the hepatitis market 59
FDA introduced new guidelines for developing direct acting antiviral agents for HCV 59
Leading drugs in development 60
Profiles of key pipeline products 61
Phase III drugs 61
Telaprevir (VX-950) – Vertex/J&J/ Mitsubishi Tanabe 61
Boceprevir (SCH 503034) – Merck 64
Heplisav – Dynavax 66
Phase IIb drugs 68
Vaniprevir (MK-7009) – Merck 68
TMC435 (TMC435350) – Medivir/J&J 69
Alisporivir (Debio 025) – Debiopharm/ Novartis 70
Danoprevir (ITMN-191/RG7227) – Roche 72
BI 201335 – Boehringer Ingelheim 73
RG7128 – Roche/ Pharmasset 75
PEG-Interferon lambda (PEG-rIL-29) – BMS/ ZymoGenetics 76
Pipeline forecast of leading drugs in development 78
Chapter 4 Competitive landscape 79
Summary 79
Introduction 80
Competitive positioning of the leading players in the global hepatitis market 80
Roche 81
Sales focus by drug class 81
Regional sales distribution 82
Marketed product portfolio 84
Pipeline analysis 85
Strategic and growth analysis 86
Drivers of growth 86
Resistors of growth 87
Merck & Co. (Merck) 87
Sales focus by drug class 88
Regional sales distribution 88
Marketed product portfolio 90
Pipeline analysis 91
Strategic and growth analysis 92
Drivers of growth 92
Resistors of growth 92
GlaxoSmithKline (GSK) 93
Sales focus by drug class 93
Regional sales distribution 94
Marketed product portfolio 96
Pipeline analysis 98
Strategic and growth analysis 98
Drivers of growth 98
Resistors of growth 99
Bristol-Myers Squibb (BMS) 100
Sales focus by drug class 100
Regional sales distribution 101
Marketed product portfolio 101
Pipeline analysis 102
Strategic and growth analysis 103
Drivers of growth 103
Resistors of growth 104
Gilead Sciences (Gilead) 104
Sales focus by drug class 104
Regional sales distribution 105
Marketed product portfolio 106
Pipeline analysis 107
Strategic and growth analysis 108
Drivers of growth 108
Resistors of growth 109
Competitive positioning of leading generic players in hepatitis market in the 7MM 110
Chapter 5 Appendix 112
IMS data 112
Forecast factors 112
Epidemiology forecast 112
Market forecast 113
Glossary/Abbreviations 113
Table of figures
Figure 1: 7MM hepatitis market share by region (%), 2009 35
Figure 2: Relative positions of the 7MM in the global hepatitis market, 2009 35
Figure 3: Key drugs in late-stage development 60
Figure 4: Roche's global hepatitis sales by drug class ($m), 2009 82
Figure 5: Roche's hepatitis franchise market performance, 2006–09 84
Figure 6: Merck's global hepatitis sales by drug class ($m), 2009 88
Figure 7: Merck's hepatitis franchise market performance, 2006–09 90
Figure 8: GSK's hepatitis sales by drug class ($m), 2009 94
Figure 9: GSK's hepatitis franchise market performance, 2006–09 96
Figure 10: BMS' hepatitis sales by drug class ($m), 2009 100
Figure 11: Gilead's hepatitis sales by drug class ($m), 2009 104
Figure 12: Gilead's hepatitis franchise market performance, 2006–09 106
Figure 13: Competitive positioning of the top 10 generic players in the 7MM, 2009 111
Table of tables
Table 1: Worldwide endemicity of HAV infection 19
Table 2: Estimated prevalence of chronic hepatitis B across the 7MM, 2009 23
Table 3: Forecast epidemiology of chronic hepatitis B across the 7MM, 2009–15 24
Table 4: Estimated prevalence of chronic hepatitis C across 7MM, 2009 27
Table 5: Forecast epidemiology of chronic hepatitis C across 7MM, 2009–15 29
Table 6: Global hepatitis market by geography ($m), 2009 34
Table 7: Global hepatitis market sales by drug class, ($m), 2009 36
Table 8: Hepatitis market sales by drug class in the US, ($m), 2009 37
Table 9: Hepatitis market sales by drug class in Japan ($m), 2009 37
Table 10: Hepatitis market sales by drug class in EU5 ($m), 2009 38
Table 11: Hepatitis market sales by drug class in BRIC ($m), 2009 39
Table 12: Leading brands in the global hepatitis market ($m), 2009 40
Table 13: Leading brands in viral hepatitis ($m), 2009 47
Table 14: Leading brands in hepatitis vaccines ($m), 2009 48
Table 15: Leading brands in hepatitis immunoglobulin ($m), 2009 48
Table 16: Generic hepatitis market in 7MM ($m), 2009 52
Table 17: Generic hepatitis market sales by drug class in 7MM ($m), 2009 52
Table 18: Leading generic brands in the 7MM hepatitis market ($m), 2009 53
Table 19: Global hepatitis market sales forecast ($m), 2009–15 54
Table 20: Leading hepatitis brands sale forecast ($m), 2009 55
Table 21: An overview of telaprevir (VX-950) 61
Table 22: Details of Phase III studies of telaprevir 62
Table 23: An overview of boceprevir (SCH 503034) 64
Table 24: Details of Phase III studies of boceprevir 65
Table 25: Result of SPRINT-2 clinical trial in different cohorts 66
Table 26: An overview of Heplisav 67
Table 27: An overview of vaniprevir 68
Table 28: An overview of TMC435 69
Table 29: An overview of alisporivir 71
Table 30: An overview of danoprevir 73
Table 31: An overview of BI 201335 74
Table 32: An overview of RG7128 75
Table 33: An overview of PEG-Interferon lambda 77
Table 34: Sales forecast for leading drugs in development ($m), 2009–15 78
Table 35: Leading players in the global hepatitis market ($m), 2009 81
Table 36: Regional sales distribution of Roche in 7MM and BRIC ($m), 2009 83
Table 37: Performance of Roche's hepatitis products ($m), 2009 84
Table 38: Roche's hepatitis R&D pipeline, July 2010 86
Table 39: Regional sales distribution of Merck in 7MM and BRIC ($m), 2009 89
Table 40: Merck's hepatitis products portfolio ($m), 2009 91
Table 41: Merck's hepatitis R&D pipeline, July 2010 92
Table 42: Regional sales distribution of GSK in 7MM and BRIC ($m), 2009 95
Table 43: GSK's hepatitis products portfolio, ($m), 2009 98
Table 44: Regional sales distribution of BMS in 7MM and BRIC, ($m), 2009 101
Table 45: BMS's hepatitis products portfolio, ($m), 2009 102
Table 46: BMS's hepatitis R&D pipeline, May 2010 103
Table 47: Regional sales distribution of Gilead in 7MM and BRIC, ($m), 2009 105
Table 48: Gilead's hepatitis products portfolio, ($m), 2009 106
Table 49: Gilead's hepatitis R&D pipeline, July 2010 108
Table 50: Leading generic players in hepatitis market in the 7MM, ($m), 2009 110
To order this report:
Pathology Industry: The Hepatitis Market Outlook to 2015: Competitive landscape, market size, pipeline analysis and growth opportunities
Check our Company Profile, SWOT and Revenue Analysis!
Nicolas Bombourg |
|
Reportlinker |
|
Email: [email protected] |
|
US: (805)652-2626 |
|
Intl: +1 805-652-2626 |
|
SOURCE Reportlinker
Share this article